Wednesday, December 1, 2010

ANDAs: Impurities in Drug Products

ANDAs: Impurities in Drug Products
US FDA has issued recommendations In Nov 2010 on what chemistry, manufacturing, and controls (CMC) information sponsors should include regarding the reporting, identification, and qualification of impurities that are classified as degradation products in drug products when submitting:

* Original abbreviated new drug applications (ANDAs)

*ANDA supplements for changes that may affect the quantitative or qualitative degradation product profile

They have also provided recommendations for establishing acceptance criteria for degradation products (specifically, degradation products of the active ingredient or reaction products of the active ingredient with an excipient(s) and/or immediate container/closure system) in generic drug products. The recommendations document replaces on issued in 1998.

FDA in the issued document that it is not establish legally enforceable rather it is a current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.
US FDA has issued this document for the following reasons:

1. To update information on listing of degradation products, setting acceptance criteria, and qualifying degradation products (thresholds and procedures) in ANDAs in conformance with the revision of the guidance for industry on Q3B(R) Impurities in New Drug Products.

2. To remove those sections of the 1998 document containing recommendations that are no longer needed because they are addressed in the more recent Q3B(R)

The Q3B(R) has been developed by the International Conference on Harmonisation (ICH) to provide guidance on impurities in drug products for new drug applications (NDAs). However, the US FDA believes that many of the recommendations provided on impurities in drug products also apply to ANDAs.
*Lower thresholds can be appropriate if the degradation product is unusually toxic.

For example, do known safety data for this degradation product or its structural class preclude human exposure at the observed level?

A degradation product is considered qualified for ANDAs when one or more of the following conditions are met: 

When the observed level and proposed acceptance criterion for the degradation product do not exceed the level justified by the RLD.

When the degradation product is a significant metabolite of the drug substance.

When the observed level and the proposed acceptance criterion for the degradation product are adequately justified by the scientific literature.

When the observed level and proposed acceptance criterion for the degradation product do not exceed the level that has been adequately evaluated in toxicity studies.

*If considered desirable, a minimum screen (e.g.,genotoxic potential) should be conducted. A study to detect point mutations and one to detect chromosomal aberrations, both in vitro, are considered an appropriate minimum screen for genotoxicity.

*If general toxicity studies are appropriate, one or more studies should be designed to allow comparison of unqualified to qualified material. The study duration should be based on available relevant information and performed in the species most likely to maximize the potential for detecting the toxicity of a degradation product. On a case-by-case basis, single-dose studies can be appropriate, especially for single-dose drugs. In general, a minimum duration of 14 days and a maximum duration of 90 days would be considered appropriate.

ANDAs: Impurities in Drug Products:List of the types of degradation products:

ANDAs: Impurities in Drug Products: Setting Acceptance Criteria for Degradation Products

ANDAs: Impurities in Drug Products: Qualification of Degradation Products

Do you know now this website has become a most popular and most referred website in pharmaceutical industry and pharmaceutical companies and pharmaceutical manufacturers from all over the world ,for almost all topics related to Pharmaceutical Manufacturing , Pharmaceutical Regulatory Affairs and Good Manufacturing Practice for Pharmaceutical Manufacturing (c GMP guidelines ) and latest news and new drugs developments.

You may also like following articles

What is a Site Master file of a pharmaceutical company

What is Generic Drug

What is Reference Listed Drug  ? ( RLD )

What is Pharmaceutical Equivalents

What is Pharmaceutical Alternatives

What is Therapeutic Equivalents

What are Post Market studies

Why a drug is bound to protein, What is protein binding?  What is drug absorption , distribution ?

Do Physical properties contribute to drug activity.

What is drug receptor , How a drug resistance occurs

Mechanism of drug resistance

What is drug interaction

Drug interaction, and its examples

What is first pass metabolism of a drug

What is What is 510(k) Clearances ?

What is 510(k) Clearances,

Premarket Notification for medical devices - PMN or 510(k)

What is a drug interaction

Examples of drug interactions

Antibiotic Definition and classification

Antibiotic Resistance and Antibiotic resistance mechanism

Antioxidants food supplements

Vitamin D Details on FDA cautions on accurate dosage of Vitamin D

What is an antibody? what is monoclonal and polyclonal antibodies?

Terminologies In vaccine Production

Multi stage testing of Virus vaccine production

Testing of vaccines at different stages of production


Enzyme linked immunosorbent assay ELISA

Raido Immuno assay

Pharmaceutical Aseptic Manufacturing Process Terms , Terminology and Definitions.

Here are some articles which will be useful for you in further understanding of aspects of sterile dosage form manufacturing and regulatory affairs and good manufacturing practice in

pharmaceutical industry

Pharmaceutical Validation

Types of validations in pharmaceutical manufacturing

Requirements of documents for validation of sterilisation process

How to investigate OOS out of specification results

Determination of Phenol coefficient of a disinfectant

Sterility testing

Clean Room Classification

Time limitations in sterile pharmaceuticals processing

Aspects of validation of manufacturing process in sterile pharmaceuticals

Clinical Trials

Requirements of US FDA Inspections of Clinical Investigators of Clinical Trials




Controlling Pyrogens in injectable dosage forms

Media fill run process simulation aspects Validation of Aseptic Process and Sterilisation

New Drug Application (NDA) how to make a New Drug Application (NDA) to US FDA

Abbreviated New Drug Application (ANDA) What is ANDA , detailed information about ANDA preparation and submission to US FDA

How to make Investigational New Drug (IND) Application to US FDA

Drug applications submission to us fda Over the counter Drugs OTC drugs


Electronic record in pharmaceutical manufacturing industry

Good manufacturing practice in pharmaceutical industry

Pharmaceutical industry pharmaceutical companies and FDA latest updates

Here is an interesting article on world wide pharmaceutical industry and making a carrier in one of pharmaceutical companies article on Pharmaceutical Industry pharmaceutical industry

Find a Job in Pharmaceutical Company -->JOBS IN PHARMA INDUSTRY<---
To Find Pharmaceutical jobs and make a Pharmaceutical careers see here pharmaceutical companies
Here are some interesting articles on Quality assurance systems for pharmaceutical company

Quality assurance in pharma industry

Quality by design concept for pharmaceutical industry

Quality by design concept in pharmaceutical industryan explanation

Useful Books For Pharmaceutical Manufacturers and Pharmaceutical Professionals

No comments: